• Tuhura Biosciences highlighted a Phase 3 accelerated-approval study of IFx-2.0 in first-line metastatic Merkel cell carcinoma.
• Trial targets about 118 patients, with topline data expected in 2H 2027; design uses ORR primary endpoint, PFS key secondary.
• Program runs under an FDA Special Protocol Assessment; confirmatory trial not expected to be required.
• Tuhura plans to start a Phase 1b/2 trial of VISTA-inhibiting antibody TBS-2025 in mutNPM1 relapsed or refractory AML in 2H 2026.
• Company cited a $50 million credit facility and royalty transaction, projecting operating runway through Q1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.